Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$231.27 USD
-3.34 (-1.42%)
Updated Nov 12, 2024 04:00 PM ET
After-Market: $231.30 +0.03 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$231.27 USD
-3.34 (-1.42%)
Updated Nov 12, 2024 04:00 PM ET
After-Market: $231.30 +0.03 (0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth B Momentum A VGM
Zacks News
Becton Dickinson (BDX) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Becton Dickinson (BDX) delivered earnings and revenue surprises of 0.73% and 1.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Becton Dickinson, McKesson and AmerisourceBergen
by Zacks Equity Research
Becton Dickinson, McKesson and AmerisourceBergen have been highlighted in this Industry Outlook article.
The Zacks Analyst Blog Highlights Meta Platforms, Becton Dickinson, CME Group, Chipotle Mexican Grill and ParkerHannifin
by Zacks Equity Research
Meta Platforms, Becton Dickinson, CME Group, Chipotle Mexican Grill and ParkerHannifin are included in this Analyst Blog.
Top Analyst Reports for Meta Platforms, Becton Dickinson & CME Group
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Meta Platforms, Inc. (META), Becton, Dickinson and Company (BDX) and CME Group (CME).
3 Dental Supplies Stocks to Watch Amid Industry Headwinds
by Indrajit Bandyopadhyay
Here we discuss three stocks from the Dental Supplies industry that are likely to create wealth for investors - BDX, MCK and ABC.
SmileDirectClub (SDC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
SmileDirectClub (SDC) delivered earnings and revenue surprises of 18.18% and 7.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Interventional segment and Life Sciences segment's base business is expected to have driven Q4 sales.
Becton Dickinson (BDX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AmerisourceBergen (ABC) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
AmerisourceBergen (ABC) delivered earnings and revenue surprises of 0.78% and 1.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
McKesson (MCK) Lags Q2 Earnings Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of -1.14% and 0.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights The Walt Disney, Broadcom, PayPal Holdings, Becton, Dickinson and Norfolk Southern
by Zacks Equity Research
The Walt Disney, Broadcom, PayPal Holdings, Becton, Dickinson and Norfolk Southern are part of the Zacks top Analyst Blog.
Here's How Much a $1000 Investment in Becton Dickinson Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Top Research Reports for Walt Disney, Broadcom & PayPal
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Company (DIS), Broadcom Inc. (AVGO) and PayPal Holdings, Inc. (PYPL).
BD (BDX)-Biocorp's Latest Deal to Enhance Tracking Adherence
by Zacks Equity Research
BD's (BDX) newest agreement is expected to enable the care provision to transition to alternate settings and improve chronic disease outcomes.
BD's (BDX) New Cloud Software Solution to Boost Lab Workflow
by Zacks Equity Research
BD's (BDX) latest launch is expected to provide scientists with an integrated ecosystem that enables optimization of panel design, collaboration and analysis.
BD's (BDX) Latest Monkeypox PCR Assay Commercially Available
by Zacks Equity Research
BD's (BDX) new molecular RUO PCR assay is expected to aid in better managing the ongoing global monkeypox outbreak.
Quest Diagnostics (DGX) & Peers Progress With Monkeypox Testing
by Zacks Equity Research
Quest Diagnostics in its latest media report notes that demand for COVID-19 molecular diagnostic testing declined in August compared to the prior month.
BD's (BDX) Latest PFS Launch to Boost Production Efficiencies
by Zacks Equity Research
BD's (BDX) newest product offering is expected to set a new standard in performance for vaccine PFS with new and strict specifications for improved production efficiencies.
Implied Volatility Surging for BD (BDX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to BD (BDX) stock based on the movements in the options market lately.
Here's Why You Should Hold on to BD (BDX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to a few regulatory approvals and strategic deals.
BD's (BDX) Latest Collaboration to Boost Patient Outcome
by Zacks Equity Research
BD's (BDX) tie-up with Accelerate Diagnostics is expected to strengthen the fight to combat the global threat of antimicrobial resistance, thereby boosting patient care.
BD (BDX) Ties Up With LabCorp to Boost Patient Outcome
by Zacks Equity Research
BD's (BDX) latest partnership is expected to provide life-changing treatments for cancer and other diseases, thereby improving patient care.
Zimmer Biomet (ZBH) Sees Business Recovery, Global Growth
by Zacks Equity Research
Zimmer Biomet (ZBH) revenues ride on continued execution along with strong COVID recovery across most markets.
Cardiovascular Systems (CSII) Q4 Earnings, Revenues Miss Mark
by Zacks Equity Research
According to Cardiovascular Systems (CSII), strong sequential growth in each of its segments is due to procedure recovery, focused commercial strategies and the launch of products.
Nevro (NVRO) Q2 Earnings Beat Estimates, FY22 View Revised
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q2, partly owing to robust domestic performance.